A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.
Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, Windsor K, Gore I, Cantrell J, Thompson KA, Taylor WR, Barnes HM, Schiff SA, Shields JA, Cambareri RJ, Butler TP, Meister RJ, Feigert JM, Norgard MJ, Moraes MA, Helvie WW, Patton GA, Mundy LJ, Henry D, Sheridan MJ, et al.
Beveridge RA, et al. Among authors: schiff sa.
Cancer Invest. 1998;16(6):366-73. doi: 10.3109/07357909809115775.
Cancer Invest. 1998.
PMID: 9679526
Clinical Trial.